MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

295 80 Merci

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A…

denTEL Directory Enables Dental Care Providers To Connect With Right Patients

150 150 Tori

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / denTEL, a specialized oral health directory was introduced with an aim for patients to find a dentist near their location. It even helps oral health…